Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulators Exchange Info On COVID-19 Vaccines, EU Urges Pooling Resources

WHO Will Start SOLIDARITY Trial Of Untested Treatments

Executive Summary

Regulators are trying to keep sight of the bigger picture amidst disparate efforts to develop potential treatments and vaccines for the coronavirus outbreak. The World Health Organization and EU regulators are concerned that small individual studies may not be in the best interests of patients and are suggesting pooling resources. 

You may also be interested in...



Regulators Insist On Large-Scale Trials For Coronavirus Treatment Candidates

At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.

COVID-19 Vaccines: Global Regulators Define Preclinical Data Requirements

Regulators held a virtual meeting to agree on the type and extent of preclinical data needed to inform the clinical development of vaccines for COVID-19.

EU Urges Sponsors To Assess COVID-19 Impact Before Starting New Trials

New EU guidance on managing clinical trials in the context of COVID-19 requires sponsors to critically assess the feasibility of starting a new clinical trial or including new participants in an ongoing trial. A separate survey indicates that patient willingness to participate in new trials has dramatically declined due to the pandemic.

Topics

UsernamePublicRestriction

Register

PS141879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel